Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Illinois Business Review.
Press releases published on June 6, 2025

Napco (NSSC) Under Scrutiny: Investor Suit and Sales Slump Shake Investor Confidence– Hagens Berman
SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- Shares in Napco Security Technologies, Inc. (NASDAQ: NSSC) are trading down nearly 21% year-to-date, as the security technology company continues to face heightened scrutiny as it navigates both legal and …

Pilly Labs Presents Natural Single-Ingredient Supplement Line Focused on Holistic Wellness
Chicago, June 06, 2025 (GLOBE NEWSWIRE) -- Pilly Labs, a natural wellness company dedicated to harnessing the power of nature, announces the release of its comprehensive line of single-ingredient supplements designed to enhance overall well-being through …

INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Launches Investigation into EchoStar Corporation (SATS) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact Law Firm
SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman …

Marimaca Announces Results of Annual General Meeting of Shareholders
VANCOUVER, British Columbia, June 06, 2025 (GLOBE NEWSWIRE) -- Marimaca Copper Corp. (TSX: MARI) (ASX: MC2) (“Marimaca” or the “Company”) is pleased to announce the results of the votes cast by ballot at its Annual General Meeting of Shareholders held …

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced …

Magnetic North Acquisition Corp. Provides Bi-Weekly Update On Status Of Management Cease Trade Order
CALGARY, Alberta and TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Magnetic North Acquisition Corp. (TSXV: MNC; MNC.PR.A) (“Magnetic North” or the “Company”) is providing this bi-weekly update on the status of the management cease trade order granted on May 9 …

Rakovina Therapeutics Announces the Closing of Oversubscribed Private Placement of $4.9 Million
VANCOUVER, British Columbia, June 06, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered …

RESTEM to Present Phase 2/3 IIMPACT Trial Design in Idiopathic Inflammatory Myopathy at EULAR 2025 Congress
MIAMI, June 06, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced that it will present the rationale and study design …

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and …

Globalink Investment Inc. Announces Extension of the Deadline to Complete a Business Combination to July 9, 2025
New York, NY , June 06, 2025 (GLOBE NEWSWIRE) -- Globalink Investment Inc. (OTC Pink: GLLI, GLLIW, GLLIR, GLLIU) (“Globalink” or the “Company”), a special purpose acquisition company, announced today that on June 5, 2025, it caused to be deposited $0.15 …

Enovis to Participate in Upcoming Investor Conferences
Wilmington, DE, June 06, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences: Goldman Sachs 46th …

Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference
LEXINGTON, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders …

Zealand Pharma increases its share capital as a result of the exercise of employee warrants
Company announcement – No. 14 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, June 6, 2025 – Zealand Pharma A/S (“Zealand Pharma”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology …

NPWR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that NET Power Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz …

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an …

Northann Corp. Issues Statement on Recent Stock Volatility
Fort Lawn, SC, June 06, 2025 (GLOBE NEWSWIRE) -- Northann Corp. (“Northann” or the “Company”) (NYSE American: NCL), a company specializing in 3D printing and manufacturing solutions, today announced that it is not aware of any new material developments or …

NIRI Florida Announces its 2025-2026 Board of Directors
Fort Lauderdale, FL, June 06, 2025 (GLOBE NEWSWIRE) -- The Florida Chapter of NIRI: The Association for Investor Relations is pleased to announce the election of the following individuals to serve on the Board of Directors for the 2025-2026 program year: …

XOVR ETF Adds Anduril, Joining SpaceX to Offer Pre-IPO Access
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- ERShares, the first Crossover ETF that offers retail investors access to Private companies, with SpaceX as its top weight, is ushering in the next generation of investing with a new private equity position in …

OBI Pharma geht AWK-Zusammenarbeit mit TegMine Therapeutics bei der Nutzung von GlycOBI® und TegMiner™ Enabling Technologies ein
TAIPEI, Taiwan, June 06, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (OBI), ein globales, im klinischen Stadium tätiges Onkologieunternehmen, das auf die Entwicklung neuartiger Krebstherapien wie Antikörper-Wirkstoff-Konjugate (AWK) (4174. TWO) spezialisiert …

Collaboration entre OBI Pharma et TegMine Therapeutics autour des ADC, reposant sur les technologies habilitantes GlycOBI® et TegMiner™
TAIPEI, Taïwan, 06 juin 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (OBI), une société internationale d’oncologie au stade clinique, spécialisée dans le développement de nouvelles thérapies contre le cancer, telles que les conjugués anticorps-médicaments ( …